SCHEMBL1712690

SCHEMBL1712690

O=C(O)CCCCn1c[c]cn1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 3/20 0.41
PTGIR P43119 3/20 0.41
LMNA P02545 2/20 0.41
PTGS1 P23219 4/20 0.41
PTGS2 P35354 4/20 0.41
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
PMP22 Q01453 1/20 0.39
EGLN3 Q9H6Z9 1/20 0.38
FABP4 P15090 1/20 0.38
FABP5 Q01469 1/20 0.38
SLC22A6 Q4U2R8 1/20 0.36
GPR84 Q9NQS5 1/20 0.34
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
AKR1B1 P15121 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1712283 0.94 EGLN3 (0.39) TBXAS1PTGIRLMNAPTGS1PTGS2
SCHEMBL1712634 0.86 EGLN3 (0.50) LMNAEGLN3FABP4FABP5
SCHEMBL3741930 0.73 TBXAS1 (0.40) TBXAS1PTGIRLMNAPTGS1PTGS2
SCHEMBL293470 0.72 TBXAS1 (0.34) TBXAS1LMNAPTGS1PTGS2
Water SCHEMBL9845268 0.71 TBXAS1 (0.50) TBXAS1PTGIRLMNAPTGS1PTGS2
SCHEMBL5521617 0.70 TBXAS1 (0.49) TBXAS1PTGIRLMNAPTGS1PTGS2
SCHEMBL10621401 0.70 EGLN3 (0.76) TBXAS1PTGIRLMNAPTGS1PTGS2
SCHEMBL9845261 0.69 TBXAS1 (0.51) TBXAS1PTGIRLMNAPTGS1PTGS2
SCHEMBL5514714 0.69 TBXAS1 (0.51) TBXAS1PTGIRLMNAPTGS1PTGS2
SCHEMBL9845290 0.69 TBXAS1 (0.51) TBXAS1PTGIRLMNAPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-01 US disclosed
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2019-06-13 US disclosed
US-20150329491-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2015-11-19 US disclosed
EP-2345629-B1 FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES JAPAN TOBACCO INC (JP) 2015-06-03 EP disclosed
US-8871934-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2014-10-28 US disclosed
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (US) 2013-10-17 US disclosed
US-8343994-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2013-01-01 US disclosed
EP-2345629-A1 FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Japan Tobacco, Inc. (JP) 2011-07-20 EP disclosed
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329491-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC TBXAS1 1618/4885PTGIR 2041/4885LMNA 527/4885
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof FH, PCK2, PC TBXAS1 1618/4885PTGIR 2041/4885LMNA 527/4885
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC TBXAS1 1618/4885PTGIR 2041/4885LMNA 527/4885
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC TBXAS1 1618/4885PTGIR 2041/4885LMNA 527/4885
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC TBXAS1 1618/4885PTGIR 2041/4885LMNA 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.